<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39254005</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Genomic insights into mRNA COVID-19 vaccines efficacy: Linking genetic polymorphisms to waning immunity.</ArticleTitle><Pagination><StartPage>2399382</StartPage><MedlinePgn>2399382</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2399382</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2024.2399382</ELocationID><Abstract><AbstractText>Genetic polymorphisms have been linked to the differential waning of vaccine-induced immunity against COVID-19 following vaccination. Despite this, evidence on the mechanisms behind this waning and its implications for vaccination policy remains limited. We hypothesize that specific gene variants may modulate the development of vaccine-initiated immunity, leading to impaired immune function. This study investigates genetic determinants influencing the sustainability of immunity post-mRNA vaccination through a genome-wide association study (GWAS). Utilizing a hospital-based, test negative case-control design, we enrolled 1,119 participants from the Taiwan Precision Medicine Initiative (TPMI) cohort, all of whom completed a full mRNA COVID-19 vaccination regimen and underwent PCR testing during the Omicron outbreak. Participants were classified into breakthrough and protected groups based on PCR results. Genetic samples were analyzed using SNP arrays with rigorous quality control. Cox regression identified significant single nucleotide polymorphisms (SNPs) associated with breakthrough infections, affecting 743 genes involved in processes such as antigenic protein translation, B cell activation, and T cell function. Key genes identified include CD247, TRPV1, MYH9, CCL16, and RPTOR, which are vital for immune responses. Polygenic risk score (PRS) analysis revealed that individuals with higher PRS are at greater risk of breakthrough infections post-vaccination, demonstrating a high predictability (AUC = 0.787) in validating population. This finding confirms the significant influence of genetic variations on the durability of immune responses and vaccine effectiveness. This study highlights the importance of considering genetic polymorphisms in evaluating vaccine-induced immunity and proposes potential personalized vaccination strategies by tailoring regimens to individual genetic profiles.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Min-Jia</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Ping-Hsing</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Pin-Hsuan</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Big Data Center, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kao</LastName><ForeName>Zih-Kai</ForeName><Initials>ZK</Initials><AffiliationInfo><Affiliation>Department of Information Management, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Zi-Qing</ForeName><Initials>ZQ</Initials><AffiliationInfo><Affiliation>Big Data Center, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Ai-Ru</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Statistics, Tamkang University, New Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Hsiang-Ling</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biotechnology and Laboratory Science in Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiou</LastName><ForeName>Shih-Hwa</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Kung-Hao</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biosafety level 3 laboratory, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Food Safety and Health Risk Assessment, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yu-Chun</ForeName><Initials>YC</Initials><Identifier Source="ORCID">0000-0002-4124-1949</Identifier><AffiliationInfo><Affiliation>Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Big Data Center, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Family Medicine, Taipei Veterans General Hospital Yuli Branch, Hualien, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000718127">COVID-19 breakthrough infections</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="N">mRNA Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013624" MajorTopicYN="N" Type="Geographic">Taiwan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093742" MajorTopicYN="N">Breakthrough Infections</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">genetic polymorphisms</Keyword><Keyword MajorTopicYN="N">long-term memory CD8+ T cells</Keyword><Keyword MajorTopicYN="N">mRNA-based vaccines</Keyword><Keyword MajorTopicYN="N">waning immunity</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>10</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>10</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39254005</ArticleId><ArticleId IdType="pmc">PMC11404610</ArticleId><ArticleId IdType="doi">10.1080/21645515.2024.2399382</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020;383(20):1920–12. doi:10.1056/NEJMoa2022483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2022483</ArticleId><ArticleId IdType="pmc">PMC7377258</ArticleId><ArticleId IdType="pubmed">32663912</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh EE, Frenck RW Jr., Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. Safety and immunogenicity of two RNA-Based covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450. doi:10.1056/NEJMoa2027906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2027906</ArticleId><ArticleId IdType="pmc">PMC7583697</ArticleId><ArticleId IdType="pubmed">33053279</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427–2438. doi:10.1056/NEJMoa2028436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028436</ArticleId><ArticleId IdType="pmc">PMC7556339</ArticleId><ArticleId IdType="pubmed">32991794</ArticleId></ArticleIdList></Reference><Reference><Citation>Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, Khan W.. A comprehensive review of mRNA vaccines. Int J Mol Sci. 2023;24(3):24. doi:10.3390/ijms24032700.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24032700</ArticleId><ArticleId IdType="pmc">PMC9917162</ArticleId><ArticleId IdType="pubmed">36769023</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirtaleb MS, Falak R, Heshmatnia J, Bakhshandeh B, Taheri RA, Soleimanjahi H, Zolfaghari Emameh R. An insight overview on COVID-19 mRNA vaccines: advantageous, pharmacology, mechanism of action, and prospective considerations. Int Immunopharmacol. 2023;117:109934. doi:10.1016/j.intimp.2023.109934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.109934</ArticleId><ArticleId IdType="pmc">PMC9968612</ArticleId><ArticleId IdType="pubmed">36867924</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20(11):817–838. doi:10.1038/s41573-021-00283-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-021-00283-5</ArticleId><ArticleId IdType="pmc">PMC8386155</ArticleId><ArticleId IdType="pubmed">34433919</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O’Connell S, Bock KW, Minai M, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383(16):1544–55. doi:10.1056/NEJMoa2024671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2024671</ArticleId><ArticleId IdType="pmc">PMC7449230</ArticleId><ArticleId IdType="pubmed">32722908</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin Perez C, Aguilar R, Jimenez A, Salmeron G, Canyelles M, Rubio R, Vidal M, Cuamba I, Barrios D, Díaz N, et al. Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination. BMC Med. 2024;22(1):103. doi:10.1186/s12916-024-03304-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-024-03304-3</ArticleId><ArticleId IdType="pmc">PMC10921636</ArticleId><ArticleId IdType="pubmed">38454385</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, Lundgreen, KA, Reynaldi, A, Khoury, DS, Pattekar, A, et al. mRNA vaccination induces durable immune memory to SARS-CoV-2 with continued evolution to variants of concern. Science. 2021;374(6572):abm0829. doi:10.1126/science.abm0829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm0829</ArticleId><ArticleId IdType="pmc">PMC9284784</ArticleId><ArticleId IdType="pubmed">34648302</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Boyton RJ. Waning immunity to SARS-CoV-2: implications for vaccine booster strategies. Lancet Respir Med. 2021;9(12):1356–1358. doi:10.1016/S2213-2600(21)00458-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00458-6</ArticleId><ArticleId IdType="pmc">PMC8530466</ArticleId><ArticleId IdType="pubmed">34688435</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Hamada K, Jubishi D, Hashimoto H, Okamoto K, Hisasue N, Sunohara M, Saito M, Shinohara T, Yamashita M, et al. Waning cellular immune responses and predictive factors in maintaining cellular immunity against SARS-CoV-2 six months after BNT162b2 mRNA vaccination. Sci Rep. 2023;13(1):9607. doi:10.1038/s41598-023-36397-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-36397-6</ArticleId><ArticleId IdType="pmc">PMC10263378</ArticleId><ArticleId IdType="pubmed">37311763</ArticleId></ArticleIdList></Reference><Reference><Citation>Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: a review. Vaccine. 2018;36(36):5350–5357. doi:10.1016/j.vaccine.2017.07.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.07.062</ArticleId><ArticleId IdType="pmc">PMC5792371</ArticleId><ArticleId IdType="pubmed">28774561</ArticleId></ArticleIdList></Reference><Reference><Citation>Smatti MK, Alkhatib HA, Al Thani AA, Yassine HM. Will Host genetics affect the response to SARS-CoV-2 vaccines? Historical precedents. Front Med. 2022;9:802312. doi:10.3389/fmed.2022.802312.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.802312</ArticleId><ArticleId IdType="pmc">PMC8962369</ArticleId><ArticleId IdType="pubmed">35360730</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Carter B, Gifford DK. Predicted cellular immunity population coverage gaps for SARS-CoV-2 subunit vaccines and their augmentation by compact peptide sets. Cell Syst. 2021;12(1):102–7.e4. doi:10.1016/j.cels.2020.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2020.11.010</ArticleId><ArticleId IdType="pmc">PMC7691134</ArticleId><ArticleId IdType="pubmed">33321075</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovsyannikova IG, Haralambieva IH, Schaid DJ, Warner ND, Poland GA, Kennedy RB. Genome-wide determinants of cellular immune responses to mumps vaccine. Vaccine. 2023;41(44):6579–6588. doi:10.1016/j.vaccine.2023.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.09.001</ArticleId><ArticleId IdType="pubmed">37778899</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillard J, Suffiotti M, Brazda P, Venkatasubramanian PB, Versteegen P, de Jonge MI, Kelly D, Bibi S, Pinto MV, Simonetti E, et al. Antiviral responses induced by Tdap-ipv vaccination are associated with persistent humoral immunity to Bordetella pertussis. Nat Commun. 2024;15(1):2133. doi:10.1038/s41467-024-46560-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-46560-w</ArticleId><ArticleId IdType="pmc">PMC10923912</ArticleId><ArticleId IdType="pubmed">38459022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy RB, Ovsyannikova IG, Haralambieva IH, Lambert ND, Pankratz VS, Poland GA. Genome-wide SNP associations with rubella-specific cytokine responses in measles-mumps-rubella vaccine recipients. Immunogenetics. 2014;66(7–8):493–499. doi:10.1007/s00251-014-0776-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00251-014-0776-3</ArticleId><ArticleId IdType="pmc">PMC4096048</ArticleId><ArticleId IdType="pubmed">24811271</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishida N, Sugiyama M, Sawai H, Nishina S, Sakai A, Ohashi J, Khor S-S, Kakisaka K, Tsuchiura T, Hino K, et al. Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine. Hepatology. 2018;68(3):848–858. doi:10.1002/hep.29876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.29876</ArticleId><ArticleId IdType="pmc">PMC6175380</ArticleId><ArticleId IdType="pubmed">29534301</ArticleId></ArticleIdList></Reference><Reference><Citation>Menegale F, Manica M, Zardini A, Guzzetta G, Marziano V, d’Andrea V, Trentini, F, Ajelli, M, Poletti, P, Merler, S, et al. Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis. Vol. 6. JAMA Netw Open; 2023. p. e2310650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10157431</ArticleId><ArticleId IdType="pubmed">37133863</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan S, Khvorov A, Huang X, Wang C, Ainslie K, Nealon J, Yang, B, Cowling, B, Tsang, T, et al. Revisiting assumptions in test-negative studies for estimating vaccine effectiveness: the need for a clinical case definition. Res Sq. 2023;rs.3.rs–2689147. doi:10.21203/rs.3.rs-2689147/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-2689147/v1</ArticleId><ArticleId IdType="pmc">PMC10423262</ArticleId><ArticleId IdType="pubmed">37573443</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean NE, Hogan JW, Schnitzer ME. Covid-19 vaccine effectiveness and the test-negative design. N Engl J Med. 2021;385(15):1431–1433. doi:10.1056/NEJMe2113151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe2113151</ArticleId><ArticleId IdType="pmc">PMC8451180</ArticleId><ArticleId IdType="pubmed">34496195</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P, Cunningham F. The ensembl variant effect predictor. Genome Biol. 2016;17(1):122. doi:10.1186/s13059-016-0974-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-016-0974-4</ArticleId><ArticleId IdType="pmc">PMC4893825</ArticleId><ArticleId IdType="pubmed">27268795</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–425. doi:10.1016/j.cels.2015.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2015.12.004</ArticleId><ArticleId IdType="pmc">PMC4707969</ArticleId><ArticleId IdType="pubmed">26771021</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.1239303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer-Blackwell K, Ryu H, Codd AS, Parks KR, MacMillan HR, Cohen KW, Stewart TL, Seese A, Lemos MP, De Rosa SC, et al. mRNA vaccination boosts S-specific T cell memory and promotes expansion of CD45RAint temra-like CD8+ T cells in COVID-19 recovered individuals. Cell Rep Med. 2023;4(8):101149. doi:10.1016/j.xcrm.2023.101149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2023.101149</ArticleId><ArticleId IdType="pmc">PMC10439252</ArticleId><ArticleId IdType="pubmed">37552991</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai DZ, Gog JR. Waning immunity can drive repeated waves of infections. Math Biosci Eng. 2024;21(2):1979–2003. doi:10.3934/mbe.2024088.</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/mbe.2024088</ArticleId><ArticleId IdType="pubmed">38454671</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavarz B, Richards NE, Workman LJ, Patel J, Muehling LM, Canderan G, Murphy DD, Brovero SG, Ailsworth SM, Eschenbacher WH, et al. Trajectory of IgG to SARS-CoV-2 after vaccination with BNT162b2 or mRNA-1273 in an employee cohort and comparison with natural infection. Front Immunol. 2022;13:850987. doi:10.3389/fimmu.2022.850987.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.850987</ArticleId><ArticleId IdType="pmc">PMC8978955</ArticleId><ArticleId IdType="pubmed">35386716</ArticleId></ArticleIdList></Reference><Reference><Citation>Tre-Hardy M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, Della Vecchia A, Horeanga A, Papleux E, Vekemans M, Beukinga I, Blairon L, et al. Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary. J Infect. 2021;83(5):559–564. doi:10.1016/j.jinf.2021.08.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.08.031</ArticleId><ArticleId IdType="pmc">PMC8380546</ArticleId><ArticleId IdType="pubmed">34437927</ArticleId></ArticleIdList></Reference><Reference><Citation>Dexiu C, Xianying L, Yingchun H, Jiafu L. Advances in CD247. Scand J Immunol. 2022;96(1):e13170. doi:10.1111/sji.13170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.13170</ArticleId><ArticleId IdType="pubmed">35388926</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffal SM, Abbas MA. TRP channels in COVID-19 disease: potential targets for prevention and treatment. Chem Biol Interact. 2021;345:109567. doi:10.1016/j.cbi.2021.109567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2021.109567</ArticleId><ArticleId IdType="pmc">PMC8217345</ArticleId><ArticleId IdType="pubmed">34166652</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Fan J, Chen Z, Zhang M, Peng H, Liu J, Ding L, Liu M, Zhao C, Zhao P, et al. Nonmuscle myosin heavy chain IIA facilitates SARS-CoV-2 infection in human pulmonary cells. Proc Natl Acad Sci USA. 2021;118(50):118. doi:10.1073/pnas.2111011118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2111011118</ArticleId><ArticleId IdType="pmc">PMC8685683</ArticleId><ArticleId IdType="pubmed">34873039</ArticleId></ArticleIdList></Reference><Reference><Citation>Dosch SF, Mahajan SD, Collins AR. SARS coronavirus spike protein-induced innate immune response occurs via activation of the nf-κB pathway in human monocyte macrophages in vitro. Virus Res. 2009;142(1–2):19–27. doi:10.1016/j.virusres.2009.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2009.01.005</ArticleId><ArticleId IdType="pmc">PMC2699111</ArticleId><ArticleId IdType="pubmed">19185596</ArticleId></ArticleIdList></Reference><Reference><Citation>Muri J, Cecchinato V, Cavalli A, Shanbhag AA, Matkovic M, Biggiogero M, Maida PA, Moritz J, Toscano C, Ghovehoud E, et al. Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course. Nat Immunol. 2023;24(4):604–611. doi:10.1038/s41590-023-01445-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01445-w</ArticleId><ArticleId IdType="pmc">PMC10063443</ArticleId><ArticleId IdType="pubmed">36879067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110(2):177–189. doi:10.1016/S0092-8674(02)00833-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(02)00833-4</ArticleId><ArticleId IdType="pubmed">12150926</ArticleId></ArticleIdList></Reference><Reference><Citation>Frigerio JM, Dagorn JC, Iovanna JL. Cloning, sequencing and expression of the L5, L21, L27a, L28, S5, S9, S10 and S29 human ribosomal protein mRNAs. Biochim Biophys Acta. 1995;1262(1):64–68. doi:10.1016/0167-4781(95)00045-I.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0167-4781(95)00045-I</ArticleId><ArticleId IdType="pubmed">7772601</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberhardt V, Luxenburger H, Kemming J, Schulien I, Ciminski K, Giese S, Csernalabics B, Lang-Meli J, Janowska I, Staniek J, et al. Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. Nature. 2021;597(7875):268–273. doi:10.1038/s41586-021-03841-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03841-4</ArticleId><ArticleId IdType="pmc">PMC8426185</ArticleId><ArticleId IdType="pubmed">34320609</ArticleId></ArticleIdList></Reference><Reference><Citation>Kared H, Redd AD, Bloch EM, Bonny TS, Sumatoh H, Kairi F, Carbajo D, Abel B, Newell EW, Bettinotti MP, et al. SARS-CoV-2–specific CD8+ T cell responses in convalescent COVID-19 individuals. J Clin Invest. 2021;131(5):131. doi:10.1172/JCI145476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI145476</ArticleId><ArticleId IdType="pmc">PMC7919723</ArticleId><ArticleId IdType="pubmed">33427749</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Liu Y, Liu D, Zeng Q, Li L, Zhou Q, Li M, Mei J, Yang N, Mo S, et al. Time of day influences immune response to an inactivated vaccine against SARS-CoV-2. Cell Res. 2021;31(11):1215–1217. doi:10.1038/s41422-021-00541-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-021-00541-6</ArticleId><ArticleId IdType="pmc">PMC8326654</ArticleId><ArticleId IdType="pubmed">34341489</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojano E, Seoane P, Ranea JAG, Perkins JR. Regulatory variants: from detection to predicting impact. Brief Bioinform. 2019;20(5):1639–1654. doi:10.1093/bib/bby039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bby039</ArticleId><ArticleId IdType="pmc">PMC6917219</ArticleId><ArticleId IdType="pubmed">29893792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohkura N, Yasumizu Y, Kitagawa Y, Tanaka A, Nakamura Y, Motooka D, Nakamura S, Okada Y, Sakaguchi S. Regulatory T cell-specific epigenomic region variants are a key determinant of susceptibility to common autoimmune diseases. Immunity. 2020;52(6):1119–132.e4. doi:10.1016/j.immuni.2020.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.04.006</ArticleId><ArticleId IdType="pubmed">32362325</ArticleId></ArticleIdList></Reference><Reference><Citation>Avalos D, Rey G, Ribeiro DM, Ramisch A, Dermitzakis ET, Delaneau O. Genetic variation in cis-regulatory domains suggests cell type-specific regulatory mechanisms in immunity. Commun Biol. 2023;6(1):335. doi:10.1038/s42003-023-04688-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-023-04688-3</ArticleId><ArticleId IdType="pmc">PMC10050075</ArticleId><ArticleId IdType="pubmed">36977773</ArticleId></ArticleIdList></Reference><Reference><Citation>Linnik JE, Egli A. Impact of host genetic polymorphisms on vaccine induced antibody response. Hum Vaccin Immunother. 2016;12(4):907–915. doi:10.1080/21645515.2015.1119345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1119345</ArticleId><ArticleId IdType="pmc">PMC4962936</ArticleId><ArticleId IdType="pubmed">26809773</ArticleId></ArticleIdList></Reference><Reference><Citation>Picard E, Armstrong S, Andrew MK, Haynes L, Loeb M, Pawelec G, Kuchel GA, McElhaney JE, Verschoor CP. Markers of systemic inflammation are positively associated with influenza vaccine antibody responses with a possible role for ILT2(+)CD57(+) nk-cells. Immun Ageing. 2022;19(1):26. doi:10.1186/s12979-022-00284-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-022-00284-x</ArticleId><ArticleId IdType="pmc">PMC9134679</ArticleId><ArticleId IdType="pubmed">35619117</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>